GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Kamada Ltd (NAS:KMDA) » Definitions » EV-to-EBITDA

Kamada (Kamada) EV-to-EBITDA : 11.08 (As of Apr. 27, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Kamada EV-to-EBITDA?

EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Kamada's enterprise value is $248.7 Mil. Kamada's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 was $22.4 Mil. Therefore, Kamada's EV-to-EBITDA for today is 11.08.

The historical rank and industry rank for Kamada's EV-to-EBITDA or its related term are showing as below:

KMDA' s EV-to-EBITDA Range Over the Past 10 Years
Min: -183.35   Med: 7.4   Max: 166.47
Current: 11.08

During the past 13 years, the highest EV-to-EBITDA of Kamada was 166.47. The lowest was -183.35. And the median was 7.40.

KMDA's EV-to-EBITDA is ranked better than
60.68% of 707 companies
in the Drug Manufacturers industry
Industry Median: 14.03 vs KMDA: 11.08

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

As of today (2024-04-27), Kamada's stock price is $5.15. Kamada's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 was $0.150. Therefore, Kamada's PE Ratio for today is 34.33.

The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.


Kamada EV-to-EBITDA Historical Data

The historical data trend for Kamada's EV-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Kamada EV-to-EBITDA Chart

Kamada Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
EV-to-EBITDA
Get a 7-Day Free Trial Premium Member Only Premium Member Only 6.58 5.83 61.75 13.67 12.89

Kamada Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
EV-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 13.67 17.30 13.15 12.79 12.89

Competitive Comparison of Kamada's EV-to-EBITDA

For the Drug Manufacturers - Specialty & Generic subindustry, Kamada's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Kamada's EV-to-EBITDA Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Kamada's EV-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Kamada's EV-to-EBITDA falls into.



Kamada EV-to-EBITDA Calculation

Kamada's EV-to-EBITDA for today is calculated as:

EV-to-EBITDA=Enterprise Value (Today)/EBITDA (TTM)
=248.670/22.441
=11.08

Kamada's current Enterprise Value is $248.7 Mil.
Kamada's EBITDA for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $22.4 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Kamada  (NAS:KMDA) EV-to-EBITDA Explanation

EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.

Kamada's PE Ratio for today is calculated as:

PE Ratio=Share Price (Today)/Earnings per Share (Diluted) (TTM)
=5.15/0.150
=34.33

Kamada's share price for today is $5.15.
Kamada's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.150.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.

Please read Which price ratio outperforms the enterprise multiple?


Kamada EV-to-EBITDA Related Terms

Thank you for viewing the detailed overview of Kamada's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.


Kamada (Kamada) Business Description

Traded in Other Exchanges
Address
2 Holzman Street, P.O. Box 4081, Science Park, Rehovot, ISR, 7670402
Kamada Ltd is a drug-focused, plasma-derived protein therapeutics company. It is involved in the business of developing, producing, and marketing specialty therapeutics using protein purification proprietary technology. Its product portfolio consists of Glassia, Bramitob, Foster, Ixiaro, Factor-IX, and others. The company has two segments namely, Proprietary Products segment and Distribution segment. It derives the majority of its revenue from the Proprietary products segment. The firm categorizes its products in Lung Disease, Vaccines, Haemophilia, Immunoglobulins, Critical care, and Diagnostics.

Kamada (Kamada) Headlines

From GuruFocus